A sneak peek at our newest preclinical program.

INBRX-121 is the first program to be borne from our Molecular Targeted Cytokine (MTC) Platform, which combines our sdAb platform with a proprietary detuned cytokine to enable expansion of specific cell populations. INBRX-121 expands the NK cell population and enhances cytotoxicity. Its unique design makes INBRX-121 a powerful therapeutic concept with multiple clinical paths.

The Candidate

Our NKp46 Targeted Detuned IL-2.

Poised to bring NK cells to the forefront of immunotherapy with a best in class profile:

NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells
Interleukin 2 (IL-2) drives NK cell expansion and activity, but its therapeutic utility is limited due to rapid drug clearance, expansion of immunosuppressive regulatory T cells, and severe dose-limiting toxicities.
Proprietary IL2-X engineering ensures specific modulation of NK Cells without impacting T-cell subsets (Tcon and Treg)
INBRX-121 is a detuned, low-affinity IL-2 that is targeted to NKp46-expressing cells via two high-affinity single-domain antibodies (sdAb).